The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Isoprenoids as mediators of the biological effects of statins
Open accessAbstract
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol biosynthesis.Several large clinical trials have demonstrated the benefits of cholesterol lowering with these agents in the primary and secondary prevention of coronary heart disease.The overall clinical benefits observed with statin therapy, however, appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels.Recent experimental and clinical evidence indicates that some of the cholesterol-independent, or so-called pleiotropic, effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting the thrombogenic response in the vascular wall.Many of these cholesterolindependent effects reflect statins' ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules.In particular, the inhibition of small GTP-binding proteins Rho, Ras, and Rac, whose proper membrane localization and function are dependent upon isoprenylation, may play an important role in mediating the biological effects of statins. Pharmacological properties of statinsStatins bind to HMG-CoA reductase at nanomolar concentrations, leading to competitive displacement of the natural substrate, HMG-CoA, which binds at micromolar concentrations (1).In addition, inhibition of cholesterol biosynthesis is accompanied by an increase in hepatic LDL receptor, which promotes uptake and clearance of cholesterol from the bloodstream.While all statins inhibit hepatic HMG-CoA reductase to varying degrees, important structural differences exist among the statins that distinguish their lipophilicity, half-life, and potency (2).For example, one of the more potent newer statins, rosuvastatin, is relatively hydrophilic and has a greater number of bonding interactions with the catalytic site of HMG-CoA reductase compared with mevastatin, fluvastatin, simvastatin, cerivastatin, and atorvastatin (1, 3).The lipophilic statins would be expected to penetrate cell membranes more effectively than the more hydrophilic statins, causing more side effects but, at the same time, eliciting more pleiotropic effects.However, the observation that hydrophilic statins have pleiotropic effects similar to those of lipophilic statins calls into question whether there are really any cholesterol-independent effects of statins.Indeed, recent evidence suggests that some of the cholesterol-independent effects of these agents may be mediated by inhibition of hepatic HMG-CoA reductase, leading to subsequent reduction in circulating isoprenoid levels (4).This hypothesis may help explain why hydrophilic statins such as pravastatin and rosuvastatin are still able to exert cholesterol-independent benefits on the vascular wall without directly entering vascular wall cells.In this respect, the word "pleiotropic" probably does not reflect the hepatic versus nonhepatic effects of these agents. Clinical trials with statinsBecause serum cholesterol level is strongly associated with coronary heart disease (5), it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects in cardiovascular diseases.However, subgroup analysis of large clinical trials such as the 4S, WOSCOP, CARE, and HPS suggests that the clinical benefits of statins are not associated with base-line cholesterol levels or the degree of cholesterol reduction (6-9).Furthermore, in angiographic trials, clinical improvements with statins far exceed changes in the size of atherosclerotic lesions (10).It is quite likely that cholesterol lowering in these longterm trials stabilized atherosclerotic plaques and made them less prone to rupture.However, in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, statins reduced recurrent ischemic events within 16 weeks following acute coronary ischemia (11).Although the serum LDL-cholesterol was decreased by 40%, this time frame was probably far too rapid for appreciable changes in lesion size and plaque stability to occur as a consequence of cholesterol reduction.An intriguing but perplexing result of large clinical trials with statins is the reduction in ischemic stroke ( 12).Although myocardial infarction is closely associated with serum cholesterol levels, neither the Framingham Heart Study nor the Multiple Risk Factor Intervention Isoprenoids as mediators of the biological effects of statins
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the effects of statins are connected with the inhibition of the synthesis of important isoprenoids, e.g.farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ subunit of heterotrimeric G-proteins [12] , guanosine triphosphatebinding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap) [12][13][14] .”
From Statins as antifungal agents (2011) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Rho GTPases and signaling networksPreprint
Aelst, L. V., & D’Souza‐Schorey, C. (1997) · Genes & Development · doi:10.1101/gad.11.18.2295 · Cited by 2,358
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.
Kannel, W., Castelli, W., Gordon, T., & McNamara, P. M. (2020) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,160
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 301–355 of 355
Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats
Xie, F., Sun, C., Sun, L., Li, J., Chen, X., Che, H., Lu, G., Yang, B., & Ai, J. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.221 · Cited by 6
Exploring the Genetic Associations Between the Use of Statins and Alzheimer's Disease
Lee, J., Park, S., Kim, Y., Kim, H. M., & Oh, C. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.133 · Cited by 6
Statins for the treatment of Alzheimer's disease and dementia
McGuinness, B., Bullock, R. A., Craig, D., Kerr, E., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514 · Cited by 7
Jung, J., Kim, Y., Cirunduzi, A. C., Yoon, S., Bang, S., & Yang, S. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70919 · Cited by 5
Shibahashi, E., Jujo, K., Mizobuchi, K., Nakao, M., Uchigata, Y., & Yamaguchi, J. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.09.018 · Cited by 6
New Developments in Research on Vitamin K Biosynthesis
Nakagawa, K. (2010) · Eisei kagaku · doi:10.1248/jhs.56.623 · Cited by 4
Patil, D., Patwardhan, B., & Kumbhare, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801814-9.00002-7 · Cited by 4
Factors associated with statin-related adverse muscular events in adult dyslipidemic outpatients
Castro, P. F., Ribeiro, E., Dórea, E. L., Pinto, G. A., & Hirata, R. D. C. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902017000400199 · Cited by 4
Warchol, I., Góra, M., Wysocka-Kapcińska, M., Komaszyło, J., Świeżewska, E., Sojka, M., Danikiewicz, W., Płochocka, D., Maciejak, A., Tulacz, D., et al. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13053 · Cited by 4
Weninger, G., Dridi, H., Reiken, S. R., Yuan, Q., Zhao, N., Groom, L. A., Leigh, J., Liu, Y., Tchagou, C., Kang, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194490 · Cited by 3
Fibrocytes drive JAK2 V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia
Uchida, T., Shide, K., Kameda, T., Ozono, Y., Kubuki, Y., Tahira, Y., Kamiunten, A., Marutsuka, K., Akizuki, K., Karasawa, M., et al. (2026) · Blood · doi:10.1182/blood.2025032693 · Cited by 3
Muddather, H. F., Bózsity, N., Balogh, G. T., Schelz, Z., & Zupkó, I. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101253 · Cited by 3
Direkte neuronale Effekte von Statinen
Bösel, J., & Endres, M. (2005) · Der Nervenarzt · doi:10.1007/s00115-005-1963-0 · Cited by 3
Plant-Derived Isoprenoids Mediate Regulation of mTOR Signaling in Tumor Cells
Peffley, D. M., & Hentosh, P. (2012) · Springer eBooks · doi:10.1007/978-94-007-4575-9_15 · Cited by 3
Clancy, R. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21900 · Cited by 3
Modulating T cell signaling cascades by HMG‐CoA reductase inhibitors
Waiczies, S., Prozorovski, T., & Zipp, F. (2005) · Signal Transduction · doi:10.1002/sita.200500058 · Cited by 3
The Mevalonate Pathway in the Radiation Response of Cancer
Azizi, L., Hausman, H., Meyer, A. K., Wong, M., & Pajonk, F. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.03.059 · Cited by 2
Lioudakis, E., & Lucitt, M. B. (2021) · Immunometabolism · doi:10.20900/immunometab20210023 · Cited by 2
The Future of Statins: Alzheimer's Disease?
Patatanian, E., & Gales, M. A. (2005) · The Consultant Pharmacist · doi:10.4140/tcp.n.2005.663 · Cited by 2
Özerkan, F., Özdoğan, Ö., Zoghi, M., Nalbantgil, S., Yavuzgil, O., & Önder, M. R. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.02.002 · Cited by 2
Bock, C. H., Jay, A. M., Dyson, G. E., Beebe‐Dimmer, J., Coté, M. L., Hou, L., Howard, B. V., Desai, P. M., Purrington, K. S., Prentice, R. L., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4521-0 · Cited by 2
Farmacogenética e efeito antiinflamatório dos inibidores da HMG-CoA redutase
Rosendo, A. B., Dal‐Pizzol, F., Fiegenbaum, M., & Almeida, S. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000400004 · Cited by 2
Is Ozone Really a “Wonder Drug”?
Bocci, V. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9234-2_8 · Cited by 2
Wei, G., Xue, L., Zhu, Y.-D., Qian, X., Zou, L., Jin, Q., Wang, D., & Ge, G. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22699 · Cited by 2
Andela, V. B. (2004) · Cancer Research · doi:10.1158/0008-5472.2934.64.8 · Cited by 2
Jujo, K., Ueshima, D., Abe, T., Shimazaki, K., Fujimoto, Y., Tanaka, T., Murata, T., Miyazaki, T., Matsumoto, M., Tokuyama, H., et al. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100481 · Cited by 1
Núñez-Cortés, J. M., Álvarez-Sala, J. L., García-Andrade, C. R., Civeira, M. F., Novés, G. Á., & Rodríguez, Y. A. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2012.04.002 · Cited by 1
New benefits of statin treatment
Boden, G. H. (2005) · Current Diabetes Reports · doi:10.1007/s11892-005-0003-6 · Cited by 1
Myopathies induites par les médicaments
Khelfi, A., Azzouz, M., Abtroun, R., Reggabi, M., & Alamir, B. (2016) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2016.11.002 · Cited by 1
Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence
Stamerra, C. A., Giosia, P. D., Giorgini, P., Feo, M. D., Grassi, D., Ferri, C., & Sahebkar, A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24199 · Cited by 1
Acquired Disorders of Platelet Function
Küçükkaya, R. D., & López, J. A. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00130-x · Cited by 1
Statins: Are Lipid-lowering Drugs Useful in Sarcomas?
García-Castellano, J. M., Martínez-Aragón, N., García-Padrón, D., Guerra, B., Ramírez-Sánchez, M., Vera-Gutiérrez, V., Garcés-Martín, G., & Fernández‐Pérez, L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107127 · Cited by 1
Slowing the Progression of Aortic Stenosis: The Emerging Role of Bisphosphonates
Elmariah, S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4132-7_13 · Cited by 1
¿Actúan las estatinas a través de los PPARα?
Laguna, J. C. (2005) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(05)73375-1 · Cited by 1
The role of statin therapy in the management of cardiomyopathies
Ramasubbu, K., & Farmer, J. A. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0019-5 · Cited by 1
Are Statins Beneficial for Patients With Heart Failure?
Pyun, W. B. (2008) · Korean Circulation Journal · doi:10.4070/kcj.2008.38.4.185 · Cited by 1
On Statin Treatment to Prevent Sepsis in Dialysis Patients
Wanner, C. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.09.009 · Cited by 1
Treatment of Endothelial Dysfunction and Atherosclerosis by Cholesterol Lowering
Aikawa, M., & Libby, P. (2007) · doi:10.1002/9780470988473.ch21
Endothelial Dysfunction in the Metabolic Syndrome
Avogaro, A. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50019-x
Statin-Induced Muscle Toxicity
Wilke, R. A., Antonik, M., Kanin, E. I., Feng, Q., & Krauss, R. M. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139051194.015
Gómez-Gerique, J. A. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78992-5
Updates on the Treatment of Pulmonary Hypertension
Lee, S., & Chang, H. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.84.3.346
Pleiotropic effects of statins on endothelium and signaling mechanisms
Shiota, M., Izumi, Y., Nakao, T., & Iwao, H. (2006) · Folia Pharmacologica Japonica · doi:10.1254/fpj.128.161
Effects of Statins on Lymphocyte Function–Associated Antigen-1
Weitz‐Schmidt, G. (2004) · Elsevier eBooks · doi:10.1016/b978-0-7216-0380-3.50019-3
Anker, S. D., & von Haehling, S. (2005) · CRC Press eBooks · doi:10.1201/9781420048957.ch24
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2023) · doi:10.1158/1940-6207.c.6547127.v1
Saito, K., Sato, Y., Nakatani, E., Kaneda, H., Yamamoto, S., Miyachi, Y., & Itoh, H. (2023) · doi:10.1158/1940-6207.c.6547127
Plasma lipid remodeling during the early recovery phase after myocardial infarction
Myszko, M., Bychowski, J., Radziwon, P., Skrzydlewska, E., & Łuczaj, W. (2026) · Scientific Reports · doi:10.1038/s41598-026-40864-1
Salari, S., Moeinipour, Y., Elahabadi, G., Moeinipour, A., & Mohammadpour, A. H. (2026) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000872
Cellular lipids: fundamental host factors for monkeypox virus replication and pathogenesis
Nawrooz, M. S., Taher, W. M., Alwan, M., Jawad, M. J., Mushtaq, H., & Allela, O. Q. B. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04834-5
Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics
Wang, Y., & Xiao, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1836315 · Cited by 1
P. gingivalis-host interactions direct antibiotic adjuvants for periodontitis antimicrobial therapy
Liu, X., Yuan, Z., Wan, Z., Yuan, X., Wang, Y., Gao, Y., Zhang, L., Song, R., Sang, J., Wang, Y., et al. (2026) · International Journal of Oral Science · doi:10.1038/s41368-026-00448-1
The impact of phytochemicals on statin efficacy and safety: A review
Vatankhah, P., Alamdari-Palangi, V., Kian, M., Hosseinpour-Soleimani, F., Savardshtaki, A., Tajbakhsh, A., & Hashempur, M. H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179129
Ishikawa, S., Mizuno, H., Murase, K., Sasano, K., OGAWA, I., Itoh, Y., Itoh, S., & Hida, S. (2026) · Genes to Cells · doi:10.1111/gtc.70148
Metadata
- Authors
- Liao, J. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Liao, James K.
- ORCID
- Liao, James K.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-01
- Volume
- 110
- Issue
- 3
- Pages
- 285-288
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4235797558
- Cited by
- 352
- References
- 35
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 16 · 2013: 13 · 2012: 16
- FWCI
- 23.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, terpenoids, pleiotropy, cholesterol-independent effects, HMG-CoA reductase inhibition, cholesterol biosynthesis, isoprenylation, small GTPases, Rho, Ras, Rac, endothelial function, atherosclerotic plaque stability, oxidative stress, inflammation, thrombogenicity, statin adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
